Compare IBRX & HOMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBRX | HOMB |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.0B |
| IPO Year | 2015 | 2006 |
| Metric | IBRX | HOMB |
|---|---|---|
| Price | $7.94 | $26.28 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 5 |
| Target Price | $12.57 | ★ $32.40 |
| AVG Volume (30 Days) | ★ 31.4M | 1.3M |
| Earning Date | 05-18-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 3.19% |
| EPS Growth | ★ 38.71 | 19.90 |
| EPS | N/A | ★ 2.41 |
| Revenue | ★ $113,288,000.00 | N/A |
| Revenue This Year | $88.57 | $10.99 |
| Revenue Next Year | $146.98 | $5.14 |
| P/E Ratio | ★ N/A | $10.91 |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.83 | $24.23 |
| 52 Week High | $12.43 | $30.83 |
| Indicator | IBRX | HOMB |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 30.21 |
| Support Level | $2.27 | $26.24 |
| Resistance Level | $8.28 | $28.81 |
| Average True Range (ATR) | 1.03 | 0.75 |
| MACD | -0.33 | -0.23 |
| Stochastic Oscillator | 3.33 | 15.17 |
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The bank also emphasizes attracting experienced bankers, credit quality and a solid balance sheet. The bank's main source of net revenue is net interest income.